Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.53 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 9/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002244 | 1.00 | IP6K1 (0.53) | IP6K1IP6K3NFE2L2PTGS1HSD11B1 | |
| SCHEMBL2893331 | 0.82 | NFE2L2 (0.62) | NFE2L2PTGS1NQO2PTGS2APP | |
| SCHEMBL2881273 | 0.81 | AHR (0.53) | PTGS1ALOX5PTGS2FBP1MAOA | |
| SCHEMBL2881704 | 0.81 | NOTUM (0.52) | IP6K1IP6K3NFE2L2MAOAMAOB | |
| SCHEMBL2881701 | 0.81 | NOTUM (0.52) | IP6K1IP6K3NFE2L2MAOAMAOB | |
| SCHEMBL2895409 | 0.74 | SCN8A (0.41) | NQO2ALOX5PTGS2APPMAOA | |
| SCHEMBL2895408 | 0.74 | SCN8A (0.41) | NQO2ALOX5PTGS2APPMAOA | |
| SCHEMBL22468800 | 0.72 | NFE2L2 (0.78) | NFE2L2PTGS1HSD11B1NQO2ALOX5 | |
| SCHEMBL13766470 | 0.72 | NFE2L2 (0.78) | NFE2L2PTGS1HSD11B1NQO2ALOX5 | |
| SCHEMBL700051 | 0.72 | NFE2L2 (0.78) | NFE2L2PTGS1HSD11B1NQO2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | IP6K1 3570/4885IP6K3 3046/4885NFE2L2 984/4885 |
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | IP6K1 3298/4885IP6K3 3969/4885NFE2L2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.